Browse Studies — Arctuva

Phase 2

Phase 2 Study of Low Dose Tamoxifen +/- High Dose Omega-3 Fatty Acids in Overweight Postmenopausal Women at Increased Risk for Breast Cancer

This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese w…

Breast Atypical HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In Situ+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06195306

Phase 2

Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial

This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. In…

Breast Atypical Ductal HyperplasiaBreast Atypical Lobular HyperplasiaBreast Carcinoma+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06184750

Phase 2

Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-menopausal Women at High Risk for Development of Breast Cancer

This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing…

Breast Atypical HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In Situ+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05941520

Longitudinal Study Evaluating the Impact of Dietary Inflammatory Potential on Breast Cancer Risk in a Cohort of Women Followed in the Breast Cancer Prevention Clinic at the Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute

This study evaluates the association of dietary inflammatory potential with breast cancer risk. Information collected in this study may help doctors to identif…

Breast Atypical Ductal HyperplasiaBreast Atypical Lobular HyperplasiaBreast Carcinoma+2 more

Estimated

~$10 – $750

Ohio State University Comprehensive Cancer CenterNCT05178498